Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use

Fig. 6

Cytotoxicity of the final product before and after cryopreservation. Three separate apheresis and elutriation runs were performed. a At the time of product release both final product (IFNs and monocytes) and the IFNs alone were assayed for toxicity using OVCAR3 cells as the target. b Percent viable total nucleated cells (black bars) and the final product (grey bars). c Percent fresh monocytes in the RO fraction (black bars), the RO cryopreserved (light grey bars), final product fresh (dark grey bars), and final product cryopreserved (white bars). d Percent recovery from the fresh RO fraction (black bars) and cryopreserved RO fraction (grey bars). e Percent viability of the fresh final product (black bars) and cryopreserved product (grey bars). f Stability of the product measured by monocyte viability at 0 h (black bars), 2 h (light grey bars), and 4 h (dark grey bars)

Back to article page